cyrilzakka/clinical-trials huggingface dataset:
Preoperative Antiseptic in Newborn Circumcision Comparison of Povidone Iodine and Hypochlorous Acid Used

Comparison of Povidone iodine and Hypochlorous acid used as a Preoperative Antiseptic in Newborn Circumcision abstract

Aim:

Circumcision is one of the most common surgical procedures in all age groups. Before the circumcision procedure, asepsis is provided with a surface disinfectant. Various methods can be used for this process. Povidone iodine, which has been used for years during the transition from traditional circumcision methods to surgical circumcision methods; tissue damage, allergic reactions and increase in pain level. For this reason, the investigators aimed to compare it with Hypochlorous acid (Crystalin), which is a less toxic and more physiological antiseptic solution.

Material and Method:

Newborns to be circumcised randomly were divided into two groups as Hypochlorosis group and Povidone iodine group. At the beginning of the circumcision procedure, a culture was taken in the form of a prepucial swab 1 minute after the cleaning of the local area and the inner surface of the prepuce. Then circumcision was performed. Culture results and complications were compared.

It is aimed to compare two solutions used for cleaning the operation area in newborn circumcision.It was conducted to compare the antibacterial activity of povidone iodine and hypochlorous.

Eligibility Criteria:
Inclusion Criteria:

* male
* newborn,

Exclusion Criteria:

* hipospadias,
* epispadias,
* urinary infectious
Changes in Metabolic Status in Patients With Total Thyroidectomy

This study objective is to evaluate the change in mitochondrial uncoupling protein 2 (UCP2) mRNA expression as function of thyroid activity (TSH, T3 and Free T4).

Blood will be drown before thyroidectomy, 2 weeks after the operation and 3-4 month after the operation.

Eligibility Criteria:
Inclusion Criteria:

* Patients who were diagnosed with thyroid carcinoma and are going to have total thyroidectomy.
* Patients with unbalanced thyroid hormones.
* Aged 18-65 years at the time of screening.
* Provision of written informed consent.

Exclusion Criteria:

* Patients with Diabetes.
* Patients with any other chronic inflammatory diseases.
* Steroid treatment.
Non-Invasive Positive Pressure Ventilation Management of High Altitude Pulmonary Edema

Trial of Non-Invasive Positive Pressure Ventilation Management of High Altitude Pulmonary Edema

Patients in the Everest area will assessed for evidence of acute HAPE. Subjects will be randomized and assigned to standard care options or treatment with Non-Invasive Positive Pressure Ventilation.

Eligibility Criteria:
Inclusion Criteria:

* Healthy adults (age 18-80)
* Travel through Pheriche, Nepal
* Diagnosis of HAPE by symptoms, vital signs, and lung ultrasound

Exclusion Criteria:

* History of chronic respiratory conditions (asthma, COPD, ILD)
* Concomitant pneumonia or aspiration, cardiomyopathy, congestive heart failure
* Kidney disease
* Neurologic disorder
* Cognitive disorder
* Temporary altered mental status
* Use of phosphodiesterase inhibitors or nifedipine prior to diagnosis of HAPE
* Age under 18 or over 80
* Pregnancy
VieScope in Patients With an Expected Difficult Airway

Patients requiring endotracheal intubation for elective surgery with an expected difficult airway are randomized to be intubated either by a) VieScope or b) videolaryngoscopy.

Tracheal intubation is required for different surgical procedures for mechanical ventilation and to prevent aspiration of secretions. In patients with an expected difficult airway, tracheal intubation is often performed by videolaryngoscopy (VL). However, this technique has limitations and may fail due to insufficient visualization of the larynx. A new device has been introduced that consists of an illuminated straight plastic tube for laryngoscopy (VSC, Vie Scope, Adroit Surgical, Oklahoma City, OK, USA) that enables for indirect intubation over a stylet.

So far, the VSC has shown promising results in manikin studies for intubation in normal and difficult airways. We aim to test the VSC in patients compared to videolaryngoscopy in a prospective randomized non-inferiority trial.

Patients will be assessed for eligibility in the Anesthesiology Pre-assessment Clinic of the University Medical Center Hamburg-Eppendorf prior to elective surgery. All patients receive a structured preoperative airway assessment.

Patients are randomized 1:1 to either intervention or control group. Patients randomized to the intervention group will be intubated with the VSC. Patients randomized to the control group are intubated with a MacIntosh type videolaryngoscope (CMAC, Storz, Germany).

Eligibility Criteria:
Inclusion Criteria:

* Patients requiring general anesthesia with transoral tracheal intubation for elective surgery
* Age ≥ 18
* Preoperative airway assessment reveals an expected difficult airway (rated by the responsible anesthetist in the Pre-assessment Clinic based on the existing in-house algorithm)

Exclusion Criteria:

* Pregnant or breastfeeding woman
* Confirmed indications for awake fiberoptic intubation especially due to enoral, pharyngeal tumors, abscesses or other processes
* Planned endotracheal intubation without deep anesthesia or neuromuscular blocking agents (e.g. awake videolaryngoscopy)
* Required transnasal tracheal intubation (e.g. for surgical reasons)
* Requirement of special endotracheal tubes such as laser or RAE tubes for surgical reasons
* Patients at risk for pulmonary aspiration who qualify for rapid sequence induction
* Loose teeth
* Denial of consent
Raspberry Ketone Intake Upregulates Circulating FGF21 and Induces Energy Expenditure in Humans

To investigate the molecular mechanism of raspberry ketone on regulating obesity, the investigators studied the effect of raspberry ketone intake on FGF21 in plasma.

The age of the volunteers were 18-60 years old, both male and female, without diabetes, hypertension and other diseases.

After ingestion of raspberry ketone (500mg), 2ml of blood was collected at 0 hours, 3 hours and 6 hours , and the FGF21 content in plasma was measured using a commercial reagent kit.

In addition, the investigators also studied the effect of raspberry ketone intake on energy metabolism 0 hours, 0.5 hours, 3 hours and 6 hours after consuming raspberry ketone (500mg).


Eligibility Criteria:
Inclusion Criteria:

No drugs were taken before the human study

Exclusion Criteria:

Patients with hypertension
Effects of Rehabilitation Combined With a Maintenance Program Compared to Rehabilitation Alone in Post-COVID-19

Infection with SARS-CoV-2 virus leads to persistent symptoms for more than 12 weeks in 15% of cases ("post-COVID syndrome"). Symptoms like fatigue, dyspnoea, limitations in physical performance and activities, head ache, anxiety symptoms, and depression are heterogenous which limit physical health and participation in daily life activities.

In the last years, multidisciplinary rehabilitation programs showed benefits in quality of life and symptom intensity in patients with post-COVID. Therefore, rehabilitation programs are recommended for individuals with Post-COVID by official sites like the German Society of Pulmonology and the European Respiratory Society.

Own first data (published at the ERS conference 2023) revealed that one the one hand, inpatient rehabilitation is effective, however, on the other hand, it is challenging to maintain these effects after completing the program. Therefore, the aim of this study is to sustain these benefits by using a digital maintenance program following the rehabilitation program compared to usual care.


Eligibility Criteria:
Inclusion Criteria:

* Post-COVID-syndrome (Definition WHO)
* Entered the rehabilitation process at the Schoen Klinik Berchtesgadener Land

Exclusion Criteria:

* No internet access
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

The main purpose of this study is to investigate efficacy, pharmacokinetics and safety of the drug in pediatric participants with moderately to severely active ulcerative colitis (UC).

Participants who complete the study will have the option to enter the long-term extension Study I6T-MC-AMAZ (AMAZ).

Eligibility Criteria:
Inclusion Criteria:

* Males or females weighing ≥10 kg and ≥2 and \<18 years old at the time of consent for screening.
* Have moderate to severe UC.
* Have failed corticosteroids, biologics, (for example, anti-tumor necrosis factor (TNF) antibodies or anti-integrin antibodies), immunomodulators (for example, azathioprine, thiopurines or methotrexate) or Janus Kinase (JAK)-Inhibitor treatment.
* Have UC at least 3 months in duration before baseline, which includes endoscopic evidence of UC corroborated by a histopathology report.

Exclusion Criteria:

* Have Crohn's disease, Inflammatory Bowel Disease Unclassified, ulcerative proctitis or primary sclerosing cholangitis.
* Have immune deficiency syndrome.
* Previous bowel resection or intestinal surgery.
* Evidence of toxic megacolon.
* History or current evidence of cancer of the gastrointestinal tract.
Feasibility of Blood Glucose Control With the Space TGC System in Medical ICU Patients

Hyperglycemia is common in critically ill patients and associated with an adverse outcome. Thus, glycaemic control is an important issue in critical care. Despite extensive efforts of the intensive care unit staff difficulties were experienced in achieving efficient and safe glucose control. A fully automated algorithm may help to overcome some of these limitations by excluding intuitive interventions and integrating relevant clinical data in the decision-making process. Space GlucoseControl (TGC system) is a decision support system which helps to achieve safe and reliable blood glucose control in the desired ranges. Information on parenteral and enteral nutrition is automatically integrated into the calculations. The primary objective of the current study is to investigate the performance and usability of the Space TGC system for glucose control in medical ICU patients.


Eligibility Criteria:
Inclusion:

* age: \> 18 years of age
* stay in the ICU expected to be \> 72 h
* blood glucose \> 110 mg/dl or patient on insulin treatment

Exclusion:

* patients with hyperglycaemic crisis/ketoacidosis due to insulin deficiency.
* known or suspected allergy to insulin
* any disease or condition which the investigator or treating physician feels would interfere with the trial or the safety of the patient (i.e., liver failure, other fatal organ failures)
* moribund patients likely to die within 24 hours
Vedic Medical Astrology in Essential Hypertension

Previous studies have explored the correlation and impact of astrological events in relation of diseases, health concerns and relationship between birth chart and disease risk. Cardiovascular conditions, sleep and fertility were found significantly associated with moon phase. However, to best of our knowledge no study has documented the impact of astrological intervention in disease management.

This is a randomised, multi-center, double blind placebo controlled clinical trial with two parallel arms. This trial aims to evaluate the effectiveness of Vedic medical astrological intervention for patients with mild to moderate hypertension,with respect to decreasing their blood pressure and improving their quality of life.


Eligibility Criteria:
Inclusion Criteria:

* Patients age between 35 and 60 years old, male and female;
* Patients who meet the diagnostic criteria of essential hypertension (
* Patients taking antihypertensive drugs under the supervision of physicians.
* Patients having understanding of our study and willing to comply with astrological protocol.
* Informed consent

Exclusion Criteria:

* Patients who have been diagnosed as secondary hypertension or malignant hypertension
* Patients with comorbid conditions
* Patients with a chronic disease associated or psychiatric conditions which might not suitable for the study
* Patients who had been treated with any other alternative or complementary medicine during the previous three months
Enumeration and Molecular Characterization of Circulating Tumour Cells in Women With Metastatic Breast Cancer

Women with metastatic breast cancer, receiving first line treatment of any kind (chemotherapy, endocrine treatment or treatment with antibodies) will be included in this trial. In connection to treatment, blood samples for determination and enumeration of circulating tumour cells will be collected at different time points. Serum and plasma will be collected and stored for future analysis of RNA and DNA.


Eligibility Criteria:
Inclusion Criteria:

* Women with metastatic breast cancer
* ECOG performance status 0-2
* Age over18 years
* Signed informed concent
* Predicted life expectancy over 2 months
* Planned for first line systemic treatment for metastatic disease (chemotherapy, antibody treatment or endocrine treatment)
* Standard imaging evaluation within 4 weeks of inclusion
* Planned for standard imaging within 16 weeks after start of therapy

Exclusion Criteria:

* Prior medical therapy for metastatic disease (prior adjuvant chemotherapy, radiotherapy or endocrine therapy is permitted)
* Inability to understand information about the study
* Other malignant disease with the exception of curatively treated basal cell or squamous cell cancer of the skin and cancer in situ of the cervix
The Change of Urinary Angiotensinogen Excretion After Valsartan Treatment in Patients With Persistent Proteinuria

This study is a multicenter, prospective, interventional study. It does not have a control group. All participants will receive 160 mg valsartan for 8 weeks. Among them, the patients with persistent proteinuria (defined as proteinuria more than 1 g/g after 8 weeks treatment of valsartan) will receive 320 mg valsartan for further 16 weeks. Participants who did not receive any ACEI or ARB previously will have a titration period for 4 weeks (80 mg for 4 weeks, 160 mg for 4 weeks, and then 320 mg for 16 weeks).

The investigators will evaluate the change of urinary angiotensinogen excretion between at baseline, at 8 weeks, and 24 weeks.


Eligibility Criteria:
Inclusion Criteria:

* Chronic kidney disease patients with

  * proteinuria of 1 - 10 g/day,
  * stable and controlled blood pressure (100/60 mmHg - 160/100 mmHg),
  * stable renal function with GFR ≥ 30 mL/min/ m2,
  * diabetes or non-diabetes

Exclusion Criteria:

* Uncontrolled diabetes (defined as HbA1c \> 9.0%)
* Immunosuppressive treatment within 6 months
* Intractable edema
* Hyperkalemia (\>5.5 mEq/L) or Hypokalemia (\< 3.5 mEq/L)
Cold Argon Plasma (CAP) Application in the Wound Treatment After Open Hemorrhoidectomy

This is single-center, prospective, randomized study

This study will include patients with 3-4 stage hemorrhoids. They will undergo an operation of open hemorrhoidectomy. Patients will be divided into a study group and a control group. Study group patients during a post-operation period except a standard treatment (antiseptic solutions and antibacterial and wound healing ointments) of a post-operation wound will be treated with cold argon plasma. Control group patients will be treated with a standard treatment. Wound healing speed will be researched.

Eligibility Criteria:
Inclusion Criteria:

* 3-4 stage hemorrhoids
* 3 hemorrhoids

Exclusion Criteria:

* patients underwent anal canals intervention
* acute hemorrhoids
* inflammatory bowel disease
* co-morbidity diseases of anal canal and perianal area
* concurrent conditions in the stage of decompensation
Post Study Continuation of C7 for G1D

This protocol provides ongoing access to triheptanoin for patients who did complete an initial pilot protocol, and provides the opportunity to collect long-term safety data from patients treated with triheptanoin.

Only patients who completed the initial pilot study were eligible. The study is ongoing with these patients only.

Eligibility Criteria:
Inclusion Criteria:

* Patients enrolled in the pilot trial (UTSW 122010-186)

Exclusion Criteria:

* Subjects who did not complete the pilot trial (UTSW 122010-186)
Aminophylline on Perioperative Lung Mechanics in COPD Morbidly Obese Patients Undergoing Laparoscopic Bariatric Surgery

The aim of this study is to evaluate the usefulness of adding aminophylline to dexmedetomidine intravenous infusion intraoperatively on oxygenation and lung mechanics in chronic obstructive pulmonary disease (COPD) morbidly obese patients undergoing bariatric surgery.

Bariatric surgery is considered the most effective treatment for patients suffering from morbid obesity, as it results in maintained loss of weight and clear impact on the comorbidities related to obesity. However, despite the advantages of anesthesia, it can have detrimental effects on the recovery of obese patients who have a high prevalence of respiratory conditions and sleep disorders.

Obesity is usually related to other respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD). According to a meta-analysis encompassing more than 300,000 adult patients, obesity and asthma were interlinked, and as BMI increased, a higher risk of asthma was noticed.

The use of dexmedetomidine infusion in morbid obese patients was assessed by many clinical trials. They revealed that the use of dexmedetomidine has the same analgesic effect as the use of fentanyl with greater hemodynamic stability obtained with the use of dexmedetomidine. Dexmedetomidine has the advantage of having no respiratory depressant effect. Also, it has an amnestic effect. Dexmedetomidine does not affect the sleep pattern and maintains the airway patency.

Aminophylline is a compound of theophylline with ethylenediamine and most common uses in the airway obstruction such as asthma and COPD. primarily for its bronchodilating and central nervous stimulating effects. However, emprical evidence suggests that aminophylline, as an adenosine antagonist, can improve the recovery time from general anesthesia.

Eligibility Criteria:
Inclusion Criteria:

* Age from 20 to 60 years.
* Patients scheduled for laparoscopic bariatric surgery not exceeding three hours under general anesthesia.
* American Society of Anesthesiologists (ASA) class II to III.
* Patients who had no previous abdominal surgery.
* Patients with a body mass index (BMI) greater than 40 kg/m2and suffered obstructive lung disease diagnosed by pulmonary function tests (; forced vital capacity (FEV1\\FVC) \< 70%).
* Patients who are psychologically normal.

Exclusion Criteria:

* Patients who refuse to participate.
* Those with arrhythmia or receiving anti-arrhythmic medications.
* Those with significant coexisting diseases (e.g. kidney, heart, liver).
* Those with known allergy to any of allocated drugs.
* Those with excessive intraoperative blood loss more than allowable amount to every patient.
Clinical Trial on the Efficacy and Safety of Bemiparin in Patients Hospitalized Because of COVID-19

The 2019 coronavirus disease (Covid-19) is a new disease caused by the SARS-CoV2 virus of which many things are not yet known. Among others, there is a need to define the best therapeutic strategy to treat Covid-19, improving patients survival and reducing complications in its management, for which many different types of treatments are being tested.

The drug being tested in this clinical trial is called bemiparin. Bemiparin is a drug authorized as a prevention and as a treatment for deep vein thrombosis (blood clots in one or more veins, generally in the legs) and venous thromboembolism (when the clot can detach and lodge in other organs such as the lungs). Covid-19 patients have been shown to be at increased risk of developing clotting problems such as those described above.

In this context, this clinical trial is being carried out to find out if certain doses of bemiparin can contribute to better management of the disease.


Eligibility Criteria:
Inclusion Criteria:

1. Informed consent.
2. Age of 18 years or more.
3. Patient with suspected COVID-19 and who meets hospitalization criteria.
4. D-dimer\> 500 ng / ml.
5. Clinical characteristics highly compatible with SARS-CoV-2 infection and confirmation by RT-qPCR at baseline or in the second sample in case of a first negative test and clinical suspicion remains.
6. Patient admitted to hospital

Exclusion Criteria:

1. ICU admission criteria.
2. Need for invasive or not invasive mechanical ventilation
3. Pregnancy.
4. Creatine clearance \<30 ml / min (Cockroft-Gault).
5. Severe liver or pancreatic function disorder.
6. Acute bacterial endocarditis and slow endocarditis.
7. Patient previously anticoagulated (although it is allowed to have received heparin at a previous low dose without time limit).
8. Patient with high hemorrhagic risk due to previous medical-surgical history.
9. Severe thrombocytopenia (\<80,000 platelets/ mm3) or known history of heparin-induced thrombocytopenia.
10. Active bleeding or increased risk of bleeding from haemostasis disorders or from organic lesions that are liable to bleed (eg, active peptic ulcer, hemorrhagic stroke, aneurysms, or brain malignancies).
11. Damage or surgical interventions in the central nervous system, eyes and ears that have taken place in the last 2 months.
12. Simultaneous participation in another clinical trial that could have a conflictive interaction with what it is intended to evaluate.
13. Any situation that in the opinion of the researcher could interfere with the treatment or with the evolution of the patient.